Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Blackmon

MOHS-Micrographic Surgery Paducah, KY Medical Doctor

NPI 1003133901 CMS profile 1284063

3101 Parisa Dr, Paducah, KY 42003

Open in the dashboard

General payments

$1,603

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Blackmon of Paducah, KY is reported in the CMS Open Payments database as having received $1,603 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $123 7
2024 General $289 14
2023 General $431 24
2022 General $474 35
2021 General $184 10
2020 General $16 1
2019 General $86 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Blackmon
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Joseph Blackmon were reported at $123. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Joseph Blackmon MOHS-Micrographic Surgery median Middle half National median
2019 $86 $316 $106–$785 $163
2020 $16 $162 $68–$412 $114
2021 $184 $243 $87–$654 $132
2022 $474 $300 $102–$887 $149
2023 $431 $364 $125–$1,010 $160
2024 $289 $445 $142–$1,108 $164
2025 $123 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $507 33 payments
  2. Regeneron Healthcare Solutions, Inc. $302 17 payments
  3. Novartis Pharmaceuticals Corporation $233 12 payments
  4. LEO Pharma Inc. $209 12 payments
  5. Lilly USA, LLC $92 6 payments
  6. Arcutis Biotherapeutics, Inc. $59 4 payments
  7. Pfizer Inc. $48 3 payments
  8. Sun Pharmaceutical Industries Inc. $41 2 payments
  9. Genzyme Corporation $31 2 payments
  10. ConvaTec Inc. $20 1 payment
  11. Other $64 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,582 95 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT $268 15 payments
  2. SKYRIZI Immunology $196 15 payments
  3. ADBRY $191 11 payments
  4. COSENTYX $166 8 payments
  5. HUMIRA $138 9 payments
  6. SKYRIZI Immunology $94 5 payments
  7. TALTZ $92 6 payments
  8. EUCRISA $48 3 payments
  9. Zoryve $46 3 payments
  10. RINVOQ $46 3 payments
  11. Other $314 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

2,293

Median for Dermatology: 534

Drug cost

$13,056

Median for Dermatology: $67,151

Branded share of claims

30.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 1,065 $7,348
Mupirocin Generic 406 $2,688
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 693 $1,935
Gentamicin Sulfate Generic 16 $705
Cephalexin Generic 73 $213
Doxycycline Hyclate Generic 40 $167

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$10,287,877

Of which drugs: $9,705,107

Medicare patients

681

Average age 77

Services billed

12,124

281 women, 400 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 32%
Diabetes 30%
Chronic kidney disease 30%
Atrial fibrillation 20%
COPD 20%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Membrane graft or membrane wrap, per square centimeter Q4205 Office 534 9,304 $9,682,361

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
  • LEO Pharma Inc. $75
$75 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $66
$66 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $41
$41 — —
SKYRIZI
  • AbbVie, Inc. $38
$38 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record